Prelude Capital Management’s Collegium Pharmaceutical COLL Stock Holding History

Prelude Capital Management’s Portfolio COLL Stock Details COLL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-10,796	Closed	-$202K	–	1891
2021 Q4	$202K	Buy	+10,796	New	+$210K	0.01%	1570
2021 Q2	–	Sell	-8,871	Closed	-$210K	–	1683
2021 Q1	$210K	Sell	8,871 -4,973	-36%	-$118K	0.01%	1314
2020 Q4	$277K	Buy	+13,844	New	+$270K	0.01%	951
2020 Q3	–	Sell	-34,889	Closed	-$611K	–	1901
2020 Q2	$611K	Buy	34,889 +554	+2%	+$10.8K	0.03%	430
2020 Q1	$561K	Buy	+34,335	New	+$709K	0.04%	308
2019 Q3	–	Sell	-2,500	Closed	-$33K	–	1750
2019 Q2	$33K	Sell	2,500 -2,700	-52%	-$36.1K	﹤0.01%	1205
2019 Q1	$79K	Buy	+5,200	New	+$83.3K	﹤0.01%	1000

Other funds holding COLL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Prelude Capital Management's COLL Position: Q1 2022 in Review

Prelude Capital Management sold out of Collegium Pharmaceutical (COLL) in Q1 2022, closing a stake of 10,796 shares — an estimated $202K sold.

Prelude Capital Management first reported a position in COLL in Q1 2019 and held it in 7 quarters. The position peaked at $611K in Q2 2020. 172 funds tracked by Wall St. Rank hold COLL as of Q1 2022.

Prelude Capital Management reported no remaining Collegium Pharmaceutical position as of Q1 2022 after selling out during the quarter.
Prelude Capital Management sold 10,796 Collegium Pharmaceutical shares in Q1 2022, an estimated $202K.
Prelude Capital Management first reported a position in Collegium Pharmaceutical in Q1 2019 and held it in 7 quarters.
Prelude Capital Management's Collegium Pharmaceutical position peaked at $611K in Q2 2020.
172 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q1 2022.

Based on Prelude Capital Management's 13F filing for Q1 2022, filed 16 May 2022.